- Home
- GNFT vs TCRX Comparison
GNFT vs TCRX Comparison
Compare GNFT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- TCRX
- Stock Information
- Founded
- GNFT 1999
- TCRX 2018
- Country
- GNFT France
- TCRX United States
- Employees
- GNFT N/A
- TCRX N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- TCRX Health Care
- Exchange
- GNFT Nasdaq
- TCRX Nasdaq
- Market Cap
- GNFT 296.4M
- TCRX 257.5M
- IPO Year
- GNFT 2019
- TCRX 2021
- Fundamental
- Price
- GNFT $4.50
- TCRX $4.41
- Analyst Decision
- GNFT Strong Buy
- TCRX Strong Buy
- Analyst Count
- GNFT 1
- TCRX 5
- Target Price
- GNFT $13.00
- TCRX $11.40
- AVG Volume (30 Days)
- GNFT 6.3K
- TCRX 261.6K
- Earning Date
- GNFT 09-19-2024
- TCRX 11-12-2024
- Dividend Yield
- GNFT N/A
- TCRX N/A
- EPS Growth
- GNFT N/A
- TCRX N/A
- EPS
- GNFT 0.47
- TCRX N/A
- Revenue
- GNFT $86,225,222.00
- TCRX $9,362,000.00
- Revenue This Year
- GNFT $155.44
- TCRX N/A
- Revenue Next Year
- GNFT N/A
- TCRX $3.10
- P/E Ratio
- GNFT $9.31
- TCRX N/A
- Revenue Growth
- GNFT 175.45
- TCRX N/A
- 52 Week Low
- GNFT $3.08
- TCRX $3.73
- 52 Week High
- GNFT $6.42
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- GNFT 28.81
- TCRX 34.37
- Support Level
- GNFT $5.10
- TCRX $5.03
- Resistance Level
- GNFT $5.81
- TCRX $6.23
- Average True Range (ATR)
- GNFT 0.21
- TCRX 0.43
- MACD
- GNFT -0.16
- TCRX -0.05
- Stochastic Oscillator
- GNFT 6.13
- TCRX 5.22
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.